FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 ビュー· 09/21/23
OncLive® On Air
OncLive® On Air
0 加入者
0

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

もっと見せる

 0 コメント sort   並び替え


次に